Standards > reporting guideline > bsg-s000155


ready REporting recommendations for tumour MARKer prognostic studies

Abbreviation:REMARK


General Information
As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines provide helpful suggestions on how to present data and important elements to include in discussions.

How to cite this record FAIRsharing.org; DOI: https://doi.org/10.25504/FAIRsharing.frr5dh; Last edited: Feb. 22, 2018, 2:04 p.m.; Last accessed: Feb 24 2018 4:08 a.m.




Record updated: Nov. 30, 2016, 6:24 a.m. by The FAIRsharing Team.


Support

General

Additional Information


Tools

    No tools defined


Schemas

No XSD schemas defined


Access / Retrieve Data

Conditions of Use





Publications

REporting recommendations for tumour MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
Br. J. Cancer 2005

View Paper (PubMed) View Paper (DOI)

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Altman DG,McShane LM,Sauerbrei W,Taube SE
BMC Med 2012

View Paper (PubMed) View Paper (DOI)

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Altman DG,McShane LM,Sauerbrei W,Taube SE
PLoS Med 2012

View Paper (PubMed) View Paper (DOI)

Related Standards

Reporting Guidelines

No guidelines defined

Terminology Artifacts

No semantic standards defined

Models and Formats

No syntax standards defined


Implementing Databases (0)

No Related Databases



Credit

Record Maintainer

  • This record is in need of a maintainer. If you login, you'll be able to claim this record.

Funds

Maintains

Grant Number(s)

  • C5529 (Cancer Research United Kingdom)